Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $22.88 Consensus PT from Analysts

Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price […]

Related Keywords

United States ,American ,Piper Sandler ,Perceptive Advisors Llc ,Vanguard Group Inc ,Exchange Traded Concepts ,Nasdaq ,Securities Exchange Commission ,Acrivon Therapeutics Inc ,American International Group Inc ,Acrivon Therapeutics ,Get Free Report ,Exchange Commission ,International Group ,Traded Concepts ,Get Free ,Acrivon Predictive Precision Proteomics ,Acrivon Therapeutics Daily ,